February 21, 2024

There are many positive developments in psoriasis treatment. Novel biologics such as interleukin 23 inhibitors and small molecule inhibitors provide improved effectiveness and a wider range of choices. Progress in topical treatments utilizing microneedles and nanoparticles enhances drug delivery, while personalized medicine directed by biomarkers offers the possibility of customized therapy and improved results.  Psoriasis...

Fecal microbiota transplantation affects several inflammation-associated plasma proteins in psoriatic arthritis, suggesting systemic immune response induction, according to a recent exploratory study. Psoriatic arthritis (PsA) is an immune-mediated disease associated with alterations in the gut microbial environment. As the gut microbiota can mediate inflammatory responses, one potential intervention for PsA is fecal microbiota transplantation (FMT)....

Risankizumab exhibits significant efficacy and a favorable safety profile in treating psoriatic arthritis, according to a recent meta-analysis. Psoriatic arthritis (PsA) is an inflammatory joint disease affecting approximately 30% of psoriasis patients and 0.7% of the general population. Risankizumab, a humanized immunoglobulin G1 monoclonal antibody targeting the p19 subunit of interleukin-23, which plays a pivotal...

An observational study found an increased prevalence of headaches and migraine in psoriatic arthritis and axial spondyloarthritis patients. Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are inflammatory diseases affecting the joints, with shared genetic backgrounds and clinical manifestations. Headache affects over 50% of adults worldwide, with migraine being the most prevalent. Studies indicate a correlation...